RespiSure (Canada)This page contains information on RespiSure for veterinary use.
The information provided typically includes the following:
- RespiSure Indications
- Warnings and cautions for RespiSure
- Direction and dosage information for RespiSure
RespiSureThis treatment applies to the following species:
Mycoplasma Hyopneumoniae Bacterin
For use in swine only
PRODUCT DESCRIPTION: RespiSure is for vaccination of healthy swine as an aid in preventing chronic pneumonia caused by Mycoplasma hyopneumoniae. RespiSure contains a chemically inactivated whole cell culture of Mycoplasma hyopneumoniae, coupled with a unique oil adjuvant, Amphigen®, to enhance and prolong the immune response without causing detectable tissue damage at the injection site.
DISEASE DESCRIPTION: Mycoplasma pneumonia of swine (MPS), or enzootic pneumonia, is a widespread, chronic disease characterized by coughing, growth retardation, and reduced feed efficiency. The etiologic agent is M. hyopneumoniae; however, the naturally occurring disease often results from a combination of bacterial and mycoplasmal infections.
MPS causes considerable economic loss in all areas where swine are raised. Surveys conducted at various locations throughout the world indicate that lesions typical of those seen with MPS occur in 30%-80% of slaughter-weight swine. Because mycoplasmal lesions may resolve before hogs reach slaughter weight, the actual incidence may be higher. The prevalence of M. hyopneumoniae infection in chronic swine pneumonia has been reported to range from 25%1-93%.2 Research indicates that MPS infections can add up to 30 days to market and increase feed consumption by 0.75 lb per lb of weight gain.
Pigs of all ages are susceptible to MPS, but the disease is most common in growing and finishing swine. Current evidence indicates the M. hyopneumoniae is transmitted by aerosol or direct contact with respiratory tract secretions from infected swine. In some cases, transmission has been attributed to carrier pigs, but other evidence demonstrates that transmission among penmates can occur once a few pigs are infected.3,4 Transmission from sow to pig during lactation is possible.5 Once established, MPS occurs year after year in affected herds, varying in severity with environmental factors such as season, ventilation, and concentration of swine.
Clinical signs of MPS include a chronic nonproductive cough continuing for weeks or months, an unthrifty appearance, and retarded growth, even though the appetites of infected swine remain normal. Stunting may occur, resulting in considerable variation in size among affected pigs. Death loss associated with secondary bacterial infection and stress may occur at 4-6 months of age.
M. hyopneumoniae causes a loss of ciliary motility in the bronchial passages. Eventually the cilia are destroyed, resulting in reduction in natural defenses in the upper respiratory tract and increased susceptibility to secondary infection with bacterial agents such as Pasteurella multocida, Haemophilus parasuis, Actinobacillus pleuropneumoniae, and Bordetella bronchiseptica. Swine lungworm and roundworm larvae infections may also increase the severity of MPS.
SAFETY AND EFFICACY: Chemical inactivation renders RespiSure incapable of causing infectious disease. Necropsy data from clinical trials showed that tissue damage occurred at only 6 (1.87%) of 320 injection sites, and none of the reactions were larger than 1 cm in diameter. The oil-base adjuvant in RespiSure does not produce the major tissue damage sometimes associated with conventional oil adjuvants.
Efficacy of RespiSure was evaluated in rigorous challenge-of-immunity studies. In repeated studies, RespiSure vaccinates had between 72% and 92% less lung involvement caused by homologous and heterologous challenge strains of M. hyopneumoniae than controls. In 2 such tests, vaccinates received 2 intramuscular doses of bacterin, the first at 1 week of age, the second at 3 weeks. One week after the second vaccination, 1 group of vaccinated and nonvaccinated control pigs were challenged intranasally with a homologous strain of M. hyopneumoniae culture, the second group with a heterologous strain. About 3 weeks after challenge, all pigs were necropsied and individual lungs were evaluated for lung damage and gross lesions characteristic of M. hyopneumoniae infection and scored according to a system devised by Goodwin and Whittlestone.6 Results are presented in Figures 1 and 2.
Figure 1. Mean percentage of lung damage following challenge with homologous M. hyopneumoniae.
Figure 2. Mean percentage of lung damage following challenge with heterologous M. hyopneumoniae.
In pigs challenged with the homologous strain, mean percentage of lung damage was 4.98% in vaccinates and 27.91% in controls (an 82.16% reduction in lung damage in vaccinates when compared to controls). Mean lung damage score for pigs challenged with the heterologous strain was 1.81% for vaccinates and 19.24% for controls (90.6% reduction in lung damage in vaccinates when compared to controls).
In an independent challenge-of-immunity study conducted at Iowa State University, pigs vaccinated at approximately 6 weeks and again at 8 weeks of age with RespiSure showed evidence of less severe M. hyopneumoniae infection (1.9% mean percentage of lung damage) than nonvaccinated control pigs (7.9% mean percentage of lung damage), a 75.91% reduction in lung damage in vaccinates when compared to controls (p = <0.01). Vaccinates also had fewer lung lobes with lesions (6 of 9 vaccinates had lesions in 12 of 63 lobes) than controls (8 of 8 had lesions in 35 of 56 lobes), and the lesions were less severe.
Evaluation of lung tissue and lesions by fluorescent antibody (FA) testing revealed that 7 of 8 control pigs and 3 of 9 vaccinates were positive for M. hyopneumoniae. Based on a system rating the intensity of infection in lung lobes as measured by immunofluorescence from 1-4, the severity of vaccinates' infections (average 0.18) was 71% less than that of controls (average 0.63) (Figure 3).
Figure 3. Severity of lung infection as measured by immunofluorescence following challenge with M. hyopneumoniae (0=no infection).
Directions For Use
1. General Directions: For best results, vaccination of all swine in a herd is recommended. Shake well. Aseptically administer two 2-mL doses intramuscularly at least 2 weeks apart.
2. Primary Vaccination: Administer a single 2-mL dose to pigs at approximately 1 week of age with a booster dose 2 weeks later. Pregnant swine may be safely vaccinated at 6 weeks and 2 weeks prior to farrowing.
3. Revaccination: Dams should be revaccinated 2 weeks before farrowing. Boars should be revaccinated semiannually.
1. Store at 2°-7°C. Prolonged exposure to higher temperatures may adversely affect potency. Do not freeze.
2. Use entire contents when first opened.
3. Sterilized syringes and needles should be used to administer this vaccine.
4. Do not vaccinate within 21 days before slaughter.
5. As with many vaccines, anaphylaxis may occur after use. Initial antidote of epinephrine is recommended and should be followed with appropriate supportive therapy.
6. This product has been shown to be efficacious in healthy animals. A protective immune response may not be elicited if animals are incubating an infectious disease, are malnourished or parasitized, are stressed due to shipment or environmental conditions, are otherwise immunocompromised, or the vaccine is not administered in accordance with label directions.
1. Gois M, Kuksa F, Sisak F: Microbiological findings in the lungs of slaughter pigs. Proc 6th Int Congr Pig Vet Soc, Copenhagen, 6:214, 1980.
2. Yamamoto K, Ogata M: Mycoplasmal and bacterial flora in the lungs of pigs. Proc 7th Int Congr Pig Vet Soc, Mexico City, 7:94, 1982.
3. Farrington DO: Immunization of swine against mycoplasmal pneumonia. Proc 4th Int Congr Pig Vet Soc, Iowa State University, p. 4, 1976.
4. Etheridge JR, Cottew GS, Lloyd LC: Isolation of Mycoplasma hyopneumoniae from lesions in experimentally infected pigs. Aust Vet J 55:356-359, 1979.
5. Clark LK: Stalling mycoplasma. Hog Farm Management p. 56, Oct 1988.
6. Goodwin RFW, Whittlestone P: Br Vet J 129:456-464, 1973.
Technical inquiries should be directed to Pfizer Animal Health Technical Services, (800) 366-5288 (USA), (800) 461-0917 (Canada).
For veterinary use only
U.S. Veterinary License No. 189
Pfizer Animal Health, Exton, PA 19341, USA
Div. of Pfizer Inc., NY, NY 10017
® Registered trademark of Pfizer Products Inc; Pfizer Canada Inc., licensee
Presentation: Available in 50 dose and 250 dose vials.
NAC No.: 11980794
17,300 TRANS-CANADA HIGHWAY, KIRKLAND, QC, H9J 2M5
|Technical Services Canada:||800-461-0917|
|Technical Services USA:||800-366-5288|
|Every effort has been made to ensure the accuracy of the RespiSure information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the Canadian product label or package insert.|
Copyright © 2013 North American Compendiums. Updated: 2013-09-18